Cybin is trading down 5.6% now at $9.91, amid weaker biotech shares and a cautious broader-market backdrop.
- No clear company-specific announcement explaining the October 23 decline surfaced in the search.
- Recent coverage reiterated the expected fourth-quarter HLP003 Phase 3 readout and HLP004 study plans, without reporting new results.
- Available evidence points to sector and risk-off pressure rather than a confirmed Cybin-specific catalyst.